A systematic review to investigate the measurement properties of goal attainment scaling, towards use in drug trials

BMC Medical Research Methodology

Volumn 16, Issue 1, 2016, Pages

  Gaasterland, Charlotte M W ^a   Jansen Van Der Weide, Marijke C ^a   Weinreich, Stephanie S ^a,b   Van Der Lee, Johanna H ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Drug trials; Goal attainment scaling; Rare diseases; Systematic review; Validation

Indexed keywords

DRUG MONITORING; DRUG SCREENING; HUMAN; MOTIVATION; OUTCOME ASSESSMENT; PROCEDURES; QUESTIONNAIRE; REPRODUCIBILITY; STATISTICS AND NUMERICAL DATA;

DRUG EVALUATION; DRUG MONITORING; GOALS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); REPRODUCIBILITY OF RESULTS; SURVEYS AND QUESTIONNAIRES;

EID: 84982171113     PISSN: None     EISSN: 14712288     Source Type: Journal    
DOI: 10.1186/s12874-016-0205-4     Document Type: Article

References (84)

1. McDonald CM, Henricson EK, Abresch RT, Florence J, Eagle M, Gappmaier E, et al. The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve. 2013;48(3):357-68. doi: 10.1002/mus.23905.
2. McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Elfring GL, et al. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve. 2010;41(4):500-10. doi: 10.1002/mus.21544.
3. Mayhew A, Mazzone ES, Eagle M, Duong T, Ash M, Decostre V, et al. Development of the performance of the upper limb module for Duchenne muscular dystrophy. Dev Med Child Neurol. 2013;55(11):1038-45.
4. De Vet HC, Terwee CB, Mokkink LB, Knol DL. Measurement in medicine: a practical guide. Cambridge: Cambridge University Press; 2011.
5. Mendell JR, Csimma C, McDonald CM, Escolar DM, Janis S, Porter JD, et al. Challenges in drug development for muscle disease: a stakeholders' meeting. Muscle Nerve. 2007;35(1):8-16.
6. Kiresuk TJ, Sherman RE. Goal attainment scaling: a general method for evaluating comprehensive community mental health programs. Community Ment Health J. 1968;4(6):443-53. doi: 10.1007/bf01530764.
7. Kiresuk TJ, Smith A, Cardillo JE. Goal attainment scaling: applications, theory, and measurement. London: Psychology Press; 2014.
8. Odding E, Roebroeck ME, Stam HJ. The epidemiology of cerebral palsy: incidence, impairments and risk factors. Disabil Rehabil. 2006;28(4):183-91. doi: 10.1080/09638280500158422.
9. Pandyan AD, Gregoric M, Barnes MP, Wood D, Van Wijck F, Burridge J, et al. Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disabil Rehabil. 2005;27(1-2):2-6.
10. Steenbeek D, Ketelaar M, Galama K, Gorter JW. Goal attainment scaling in paediatric rehabilitation: a critical review of the literature. Dev Med Child Neurol. 2007;49(7):550-6. doi: 10.1111/j.1469-8749.2007.00550.x.
11. van Kuijk AA, Geurts AC, Bevaart BJ, van Limbeek J. Treatment of upper extremity spasticity in stroke patients by focal neuronal or neuromuscular blockade: a systematic review of the literature. J Rehabil Med. 2002;34(2):51-61.
12. Wade DT. Goal planning in stroke rehabilitation: evidence. Topology. 1999;6(2):37-42. http://dx.doi.org/10.1310/FMYJ-RKG1-YANB-WXRH.
13. Birks J, Craig D. Galantamine for vascular cognitive impairment. Cochrane Database Syst Rev. 2013;4:Cd004746. doi: 10.1002/14651858.CD004746.pub2.
14. Bouwens SF, van Heugten CM, Verhey FR. Review of goal attainment scaling as a useful outcome measure in psychogeriatric patients with cognitive disorders. Dement Geriatr Cogn Disord. 2008;26(6):528-40. doi: 10.1159/000178757.
15. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006;1:Cd001747. doi: 10.1002/14651858.CD001747.pub3.
16. Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, et al. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Qual Life Res. 2010;19(4):539-49.
17. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336-41.
18. Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, et al. The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. J Clin Epidemiol. 2010;63(7):737-45.
19. Terwee CB, Bot SD, de Boer MR, van der Windt DA, Knol DL, Dekker J, et al. Quality criteria were proposed for measurement properties of health status questionnaires. J Clin Epidemiol. 2007;60(1):34-42.
20. De Beurs E, Lange A, Blonk RWB, Koele P, Van Balkom AJLM, Van Dyck R. Goal attainment scaling: an idiosyncratic method to assess treatment effectiveness in agoraphobia. J Psychopathol Behav Assess. 1993;15(4):357-73.
21. Palisano RJ, Gowland C. Validity of goal attainment scaling in infants with motor delays. Phys Ther. 1993;73(10):651-60.
22. Stolee P, Awad M, Byrne K, DeForge R, Clements S, Glenny C. A multi-site study of the feasibility and clinical utility of Goal Attainment Scaling in geriatric day hospitals. Disabil Rehabil. 2012;34(20):1716-26. http://dx.doi.org/10.3109/09638288.2012.660600.
23. Yip AM, Gorman MC, Stadnyk K, Mills WG, MacPherson KM, Rockwood K. A standardized menu for Goal Attainment Scaling in the care of frail elders. Gerontologist. 1998;38(6):735-42.
24. Turner-Stokes L, Fheodoroff K, Jacinto J, Maisonobe P. Results from the Upper Limb International Spasticity Study-II (ULIS-II): a large, international, prospective cohort study investigating practice and goal attainment following treatment with botulinum toxin a in real-life clinical management. BMJ Open. 2013;3(6). http://dx.doi.org/10.1136/bmjopen-2013-002771.
25. Turner-Stokes L, Fheodoroff K, Jacinto J, Maisonobe P, Zakine B. Upper limb international spasticity study: rationale and protocol for a large, international, multicentre prospective cohort study investigating management and goal attainment following treatment with botulinum toxin A in real-life clinical practice. BMJ Open. 2013;3(3). http://dx.doi.org/10.1136/bmjopen-2012-002230.
26. Stolee P, Stadnyk K, Myers AM, Rockwood K. An individualized approach to outcome measurement in geriatric rehabilitation. J Gerontol Ser A Biol Med Sci. 1999;54A(12):M641-M7. http://dx.doi.org/10.1093/gerona/54.12.M641.
27. Rockwood K, Stolee P, Howard K, Mallery L. Use of Goal Attainment Scaling to measure treatment effects in an anti-dementia drug trial. Neuroepidemiology. 1996;15(6):330-8.
28. Woodward CA, Santa-Barbara J, Levin S, Epstein NB. The role of goal attainment scaling in evaluating family therapy outcome. Am J Orthopsychiatry. 1978;48(3):464-76.
29. Cusick A, McIntyre S, Novak I, Lannin N, Lowe K. A comparison of goal attainment scaling and the Canadian Occupational Performance Measure for paediatric rehabilitation research. Pediatr Rehabil. 2006;9(2):149-57.
30. Gordon JE, Powell C, Rockwood K. Goal attainment scaling as a measure of clinically important change in nursing-home patients. Age Ageing. 1999;28(3):275-81.
31. Rockwood K, Stolee P, Fox RA. Use of goal attainment scaling in measuring clinically important change in the frail elderly. J Clin Epidemiol. 1993;46(10):1113-8.
32. Brown DA, Effgen SK, Palisano RJ. Performance following ability-focused physical therapy intervention in individuals with severely limited physical and cognitive abilities. Phys Ther. 1998;78(9):934-47. discussion 48-50.
33. Rockwood K, Joyce B, Stolee P. Use of goal attainment scaling in measuring clinically important change in cognitive rehabilitation patients. J Clin Epidemiol. 1997;50(5):581-8.
34. Ruble L, McGrew JH. Teacher and child predictors of achieving IEP goals of children with autism. J Autism Dev Disord. 2013;43(12):2748-63. http://dx.doi.org/10.1007/s10803-013-1884-x.
35. Ruble L, McGrew JH, Toland MD. Goal attainment scaling as an outcome measure in randomized controlled trials of psychosocial interventions in autism. J Autism Dev Disord. 2012;42(9):1974-83. http://dx.doi.org/10.1007/s10803-012-1446-7.
36. Ruble LA, McGrew JH, Toland MD, Dalrymple NJ, Jung LA. A randomized controlled trial of COMPASS web-based and face-to-face teacher coaching in autism. J Consult Clin Psychol. 2013;81(3):566-72. http://dx.doi.org/10.1037/a0032003.
37. Bovend'Eerdt TJ, Dawes H, Izadi H, Wade DT. Agreement between two different scoring procedures for goal attainment scaling is low. J Rehabil Med. 2011;43(1):46-9. http://dx.doi.org/10.2340/16501977-0624.
38. Steenbeek D, Meester-Delver A, Becher JG, Lankhorst GJ. The effect of botulinum toxin type a treatment of the lower extremity on the level of functional abilities in children with cerebral palsy: evaluation with goal attainment scaling. Clin Rehabil. 2005;19(3):274-82.
39. Hartman D, Borrie MJ, Davison E, Stolee P. Use of goal attainment scaling in a dementia special care unit. Am J Alzheimers Dis. 1997;12(3):111-6. http://dx.doi.org/10.1177/153331759701200303.
40. Khan F, Pallant JF, Turner-Stokes L. Use of goal attainment scaling in inpatient rehabilitation for persons with multiple sclerosis. Arch Phys Med Rehabil. 2008;89(4):652-9. http://dx.doi.org/10.1016/j.apmr.2007.09.049.
41. Rockwood K, Howlett S, Stadnyk K, Carver D, Powell C, Stolee P. Responsiveness of goal attainment scaling in a randomized controlled trial of comprehensive geriatric assessment. J Clin Epidemiol. 2003;56(8):736-43.
42. Turner-Stokes L, Williams H, Johnson J. Goal attainment scaling: does it provide added value as a person-centred measure for evaluation of outcome in neurorehabilitation following acquired brain injury? J Rehabil Med. 2009;41(7):528-35. http://dx.doi.org/10.2340/16501977-0383.
43. Turner-Stokes L, Baguley IJ, De Graaff S, Katrak P, Davies L, McCrory P, et al. Goal attainment scaling in the evaluation of treatment of upper limb spasticity with botulinum toxin: a secondary analysis from a double-blind placebo-controlled randomized clinical trial. J Rehabil Med. 2010;42(1):81-9. http://dx.doi.org/10.2340/16501977-0474.
44. Steenbeek D, Gorter JW, Ketelaar M, Galama K, Lindeman E. Responsiveness of Goal Attainment Scaling in comparison to two standardized measures in outcome evaluation of children with cerebral palsy. Clin Rehabil. 2011;25(12):1128-39. http://dx.doi.org/10.1177/0269215511407220.
45. Stevens A, Beurskens A, Köke A, van der Weijden T. The use of patient-specific measurement instruments in the process of goal-setting: a systematic review of available instruments and their feasibility. Clin Rehabil. 2013;0269215513490178.
46. Tennant A. Goal attainment scaling: current methodological challenges. Disabil Rehabil. 2007;29(20-21):1583-8.
47. Marson SM, Wei G, Wasserman D. A reliability analysis of goal attainment scaling (GAS) weights. Am J Eval. 2009;30(2):203-16.
48. Bottomley A, Jones D, Claassens L. Patient-reported outcomes: assessment and current perspectives of the guidelines of the food and drug administration and the reflection paper of the European medicines agency. Eur J Cancer. 2009;45(3):347-53.
49. Mokkink L, Terwee C, Patrick D, Alonso J, Strat-ford P, Knol D, et al. International consensus on taxonomy, terminology, and definitionsof measurement properties for health-related patientreportedoutcomes: results of the COSMIN study. J Clin Epidemiol.
50. Rockwood K, Graham JE, Fay S, Investigators A. Goal setting and attainment in Alzheimer's disease patients treated with donepezil. J Neurol Neurosurg Psychiatry. 2002;73(5):500-7.
51. Ashford S, Turner-Stokes L. Ma of shoulder and proximal upper limb spasticity using botulinum toxin and concurrent therapy interventions: a preliminary analysis of goals and outcomes. Disabil Rehabil. 2009;31(3):220-6. http://dx.doi.org/10.1080/09638280801906388.
52. Barden HL, Baguley IJ, Nott MT, Chapparo C. Dynamic computerised hand dynamometry: Measuring outcomes following upper limb botulinum toxin-A injections in adults with acquired brain injury. J Rehabil Med. 2014;46(4):314-20.
53. Barden HLH, Baguley IJ, Nott MT, Chapparo C. Measuring spasticity and fine motor control (pinch) change in the hand after botulinum toxin-a injection using dynamic computerized hand dynamometry. Arch Phys Med Rehabil. 2014;95(12):2402-9.
54. Bonouvrie LA, Becher JG, Vles JSH, Boeschoten K, Soudant D, de Groot V, et al. Intrathecal baclofen treatment in dystonic cerebral palsy: a randomized clinical trial: The IDYS trial. BMC Pediatr. 2013;13(1). http://dx.doi.org/10.1186/1471-2431-13-175.
55. Borg J, Ward AB, Wissel J, Kulkarni J, Sakel M, Ertzgaard P, et al. Rationale and design of a multicentre, double-blind, prospective, randomized, European and Canadian study: evaluating patient outcomes and costs of managing adults with post-stroke focal spasticity. J Rehabil Med. 2011;43(1):15-22. http://dx.doi.org/10.2340/16501977-0663.
56. Demetrios M, Gorelik A, Louie J, Brand C, Baguley IJ, Khan F. Outcomes of ambulatory rehabilitation programmes following Botulinum toxin for spasticity in adults with stroke. J Rehabil Med. 2014;46(8):730-7.
57. Ferrari A, Maoret AR, Muzzini S, Alboresi S, Lombardi F, Sgandurra G, et al. A randomized trial of upper limb botulimun toxin versus placebo injection, combined with physiotherapy, in children with hemiplegia. Res Dev Disabil. 2014;35(10):2505-13.
58. Fietzek UM, Schroeteler FE, Ceballos-Baumann AO. Goal attainment after treatment of parkinsonian camptocormia with botulinum toxin. Mov Disord. 2009;24(13):2027-8. http://dx.doi.org/10.1002/mds.22676.
59. Lam K, Lau KK, So KK, Tam CK, Wu YM, Cheung G, et al. Can botulinum toxin decrease carer burden in long term care residents with upper limb spasticity? A randomized controlled study. J Am Med Dir Assoc. 2012;13(5):477-84. http://dx.doi.org/10.1016/j.jamda.2012.03.005.
60. Lam K, Wong D, Tam CK, Wah SH, Myint MWWJ, Yu TKK, et al. Ultrasound and electrical stimulator-guided obturator nerve block with phenol in the treatment of Hip adductor spasticity in long-term care patients: a randomized, triple blind, placebo controlled study. J Am Med Dir Assoc. 2015;16(3):238-46.
61. Leroi I, Atkinson R, Overshott R. Memantine improves goal attainment and reduces caregiver burden in Parkinson's disease with dementia. Int J Geriatr Psychiatry. 2014;29(9):899-905.
62. Lowe K, Novak I, Cusick A. Low-dose/high-concentration localized botulinum toxin A improves upper limb movement and function in children with hemiplegic cerebral palsy. Dev Med Child Neurol. 2006;48(3):170-5.
63. Lowe K, Novak I, Cusick A. Repeat injection of botulinum toxin A is safe and effective for upper limb movement and function in children with cerebral palsy. Dev Med Child Neurol. 2007;49(11):823-9.
64. Mall V, Heinen F, Siebel A, Bertram C, Hafkemeyer U, Wissel J, et al. Treatment of adductor spasticity with BTX-A in children with CP: a randomized, double-blind, placebo-controlled study. Dev Med Child Neurol. 2006;48(1):10-3.
65. McCrory P, Turner-Stokes L, Baguley IJ, De Graaff S, Katrak P, Sandanam J, et al. Botulinum toxin A for treatment of upper limb spasticity following stroke: a multi-centre randomized placebo-controlled study of the effects on quality of life and other person-centred outcomes. J Rehabil Med. 2009;41(7):536-44. http://dx.doi.org/10.2340/16501977-0366.
66. Molenaers G, Fagard K, Van Campenhout A, Desloovere K. Botulinum toxin A treatment of the lower extremities in children with cerebral palsy. J Child Orthop. 2013;7(5):383-7.
67. Nott MT, Barden HL, Baguley IJ. Goal attainment following upper-limb botulinum toxin-A injections: Are we facilitating achievement of client-centred goals? J Rehabil Med. 2014;46(9):864-8.
68. Olesch CA, Greaves S, Imms C, Reid SM, Graham HK. Repeat botulinum toxin-A injections in the upper limb of children with hemiplegia: a randomized controlled trial. Dev Med Child Neurol. 2010;52(1):79-86. http://dx.doi.org/10.1111/j.1469-8749.2009.03387.x.
69. Rice J, Waugh MC. Pilot study on trihexyphenidyl in the treatment of dystonia in children with cerebral palsy. J Child Neurol. 2009;24(2):176-82. http://dx.doi.org/10.1177/0883073808322668.
70. Rockwood K, Fay S, Song X, MacKnight C, Gorman M. Video-imaging synthesis of treating Alzheimer's disease I. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial. Cmaj. 2006;174(8):1099-105.
71. Rockwood K, Fay S, Jarrett P, Asp E. Effect of galantamine on verbal repetition in AD: a secondary analysis of the VISTA trial. Neurology. 2007;68(14):1116-21.
72. Rockwood K, Fay S, Gorman M, Carver D, Graham JE. The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial. BMC Neurol. 2007;7:26.
73. Rockwood K, Fay S, Gorman M. The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease. Int J Geriatr Psychiatry. 2010;25(2):191-201. http://dx.doi.org/10.1002/gps.2319.
74. Russo RN, Crotty M, Miller MD, Murchland S, Flett P, Haan E. Upper-limb botulinum toxin A injection and occupational therapy in children with hemiplegic cerebral palsy identified from a population register: a single-blind, randomized, controlled trial. Pediatrics. 2007;119(5):e1149-58.
75. Scheinberg A, Hall K, Lam LT, O'Flaherty S. Oral baclofen in children with cerebral palsy: a double-blind crossover pilot study. J Paediatr Child Health. 2006;42(11):715-20.
76. Schramm A, Ndayisaba J-P, Brinke M, Hecht M, Herrmann C, Huber M et al. Spasticity treatment with onabotulinumtoxin a: Data from a prospective german real-life patient registry. J Neural Transm. 2014(Pagination):No Pagination Specified. http://dx.doi.org/ 10.1007/s00702-013-1145-3.
77. Turner-Stokes L, Ashford S. Serial injection of botulinum toxin for muscle imbalance due to regional spasticity in the upper limb. Disabil Rehabil. 2007;29(23):1806-12.
78. Wallen MA, O'Flaherty SJ, Waugh MCA. Functional Outcomes of Intramuscular Botulinum Toxin Type A in the Upper Limbs of Children with Cerebral Palsy: A Phase II Trial. Arch Phys Med Rehabil. 2004;85(2):192-200. http://dx.doi.org/10.1016/j.apmr.2003.05.008.
79. Wallen M, O'Flaherty SJ, Waugh MC. Functional outcomes of intramuscular botulinum toxin type a and occupational therapy in the upper limbs of children with cerebral palsy: a randomized controlled trial. Arch Phys Med Rehabil. 2007;88(1):1-10.
80. Ward FA, Pulido-Velazquez M. Incentive pricing and cost recovery at the basin scale. J environ manage. 2009;90(1):293-313. http://dx.doi.org/10.1016/j.jenvman.2007.09.009.
81. Ward AB, Wissel J, Borg J, Ertzgaard P, Herrmann C, Kulkarni J, et al. Functional goal achievement in poststroke spasticity patients: The BOTOX® Economic Spasticity Trial (BEST). J Rehabil Med. 2014;46(6):504-13.
82. Bovend'Eerdt TJ, Dawes H, Sackley C, Izadi H, Wade DT. An integrated motor imagery program to improve functional task performance in neurorehabilitation: a single-blind randomized controlled trial. Arch Phys Med Rehabil. 2010;91(6):939-46.
83. Fisher K, Hardie RJ. Goal attainment scaling in evaluating a multidisciplinary pain management programme. Clin Rehabil. 2002;16(8):871-7.
84. Sheldon KM, Elliot AJ. Not all personal goals are personal: Comparing autonomous and controlled reasons for goals as predictors of effort and attainment. Personal Soc Psychol Bull. 1998;24(5):546-57. http://dx.doi.org/10.1177/0146167298245010.